Literature DB >> 16304144

Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures.

F Dal Pozzo1, G Andrei, A Holy, J Van Den Oord, A Scagliarini, E De Clercq, R Snoeck.   

Abstract

Orf virus, a member of the Parapoxvirus genus, causes a contagious pustular dermatitis in sheep, goats, and humans. Previous studies have demonstrated the activity of (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (HPMPC; cidofovir; Vistide) against orf virus in cell culture and humans. We have evaluated a broad range of acyclic nucleoside phosphonates (ANPs) against several orf virus strains in primary lamb keratinocytes (PLKs) and human embryonic lung (HEL) monolayers. HPMPC, (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6- diaminopurine (HPMPDAP), and (R)-9-[3-hydroxy-2-(phosphonomethoxy)propoxy]-2,4-diaminopyrimidine (HPMPO-DAPy) were three of the most active compounds that were subsequently tested in a virus yield assay with PLK and HEL cells by virus titration and DNA quantification. HPMPC, HPMPDAP, and HPMPO-DAPy were evaluated for their activities against orf virus replication in organotypic epithelial raft cultures from differentiated PLK cells. At the highest concentrations (50 and 20 microg/ml), full protection was provided by the three drugs, while at 5 microg/ml, only HPMPDAP and HPMPC offered partial protection. The activities of the three compounds in the raft culture system were confirmed by quantification of infectious virus and viral DNA. These findings provide a rationale for the use of HPMPC and other ANPs in the treatment of orf (contagious ecthyma) in humans and animals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304144      PMCID: PMC1315923          DOI: 10.1128/AAC.49.12.4843-4852.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy.

Authors:  C Degraeve; A De Coninck; J Senneseael; D Roseeuw
Journal:  Dermatology       Date:  1999       Impact factor: 5.366

2.  The orf virus: a disease of the farming community.

Authors:  A Crumbie
Journal:  Community Nurse       Date:  1998-06

3.  Restriction endonuclease profiles of orf virus isolates from the British Isles.

Authors:  J A Gilray; P F Nettleton; I Pow; C J Lewis; S A Stephens; J D Madeley; H W Reid
Journal:  Vet Rec       Date:  1998-08-29       Impact factor: 2.695

4.  Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.

Authors:  J Neyts; R Snoeck; J Balzarini; E De Clercq
Journal:  Antiviral Res       Date:  1991-07       Impact factor: 5.970

5.  Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system.

Authors:  R J Visalli; R J Courtney; C Meyers
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

Review 6.  The immune and inflammatory response to orf virus.

Authors:  D M Haig; C McInnes; D Deane; H Reid; A Mercer
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1997-06       Impact factor: 2.268

7.  6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity.

Authors:  J Balzarini; C Pannecouque; L Naesens; G Andrei; R Snoeck; E De Clercq; D Hocková; A Holý
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004-10       Impact factor: 1.381

8.  Immune responses of patients to orf virus infection.

Authors:  D L Yirrell; J P Vestey; M Norval
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

Review 9.  Ovine diseases. Orf.

Authors:  D M Haig; A A Mercer
Journal:  Vet Res       Date:  1998 May-Aug       Impact factor: 3.683

10.  Bullous pemphigoid complicating human orf.

Authors:  J K Murphy; I G Ralfs
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

View more
  11 in total

1.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures.

Authors:  Ilya Lebeau; Graciela Andrei; Fabiana Dal Pozzo; James R Beadle; Karl Y Hostetler; Erik De Clercq; Joost van den Oord; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

Authors:  A Scagliarini; C J McInnes; L Gallina; F Dal Pozzo; L Scagliarini; R Snoeck; S Prosperi; J Sales; J A Gilray; P F Nettleton
Journal:  Antiviral Res       Date:  2006-10-11       Impact factor: 5.970

4.  Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.

Authors:  Fabio Sonvico; Gaia Colombo; Laura Gallina; Fabrizio Bortolotti; Alessandra Rossi; Colin J McInnes; Gina Massimo; Paolo Colombo; Alessandra Scagliarini
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

5.  Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.

Authors:  Sophie Duraffour; Robert Snoeck; Marcela Krecmerová; Joost van Den Oord; Rita De Vos; Antonín Holy; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

6.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

8.  Orf virus (ORFV) infection in a three-dimensional human skin model: Characteristic cellular alterations and interference with keratinocyte differentiation.

Authors:  Mahmod Muhsen; Martina Protschka; Laura E Schneider; Uwe Müller; Gabriele Köhler; Thomas M Magin; Mathias Büttner; Gottfried Alber; Sabine Siegemund
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

Review 9.  Overview of Biologically Active Nucleoside Phosphonates.

Authors:  Elisabetta Groaz; Steven De Jonghe
Journal:  Front Chem       Date:  2021-01-08       Impact factor: 5.221

10.  Transdermal delivery and cutaneous targeting of antivirals using a penetration enhancer and lysolipid prodrugs.

Authors:  Denisa Diblíková; Monika Kopečná; Barbora Školová; Marcela Krečmerová; Jaroslav Roh; Alexandr Hrabálek; Kateřina Vávrová
Journal:  Pharm Res       Date:  2013-11-22       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.